A Japanese health ministry proposal to impose steeper price cuts on certain medicines deemed to carry poor cost-effectiveness profiles cleared…
HOME > TOP STORIES
TOP STORIES
-
ACADEMIA Subordinate of Former Employee of Novartis Pharma Participated in SMART Study; Protocol Violations Also Found
November 5, 2013
-
ACADEMIA Mismatch Found for 10% of ACR Data Between Papers, Patient Records: SMART Study
November 1, 2013
-
BUSINESS Takeda 1st Half Sales Rise 5.3% on New Portfolio, Weaker Yen
November 1, 2013
-
REGULATORY New CSIMC Healthcare Rep Nakagawa Says Against Perpetuation of Premium
October 31, 2013
-
ORGANIZATION PhRMA Makes Yet Another Case for Perpetuation of New Drug Premium
October 31, 2013
-
REGULATORY Generic Use for Anti-Allergic Agents Jumps after Pilot Leaflet Project: Kyokai Kenpo
October 30, 2013
-
REGULATORY 1st Committee Backs Japan Tobacco’s Hyperphosphatemia Treatment
October 30, 2013
-
ACADEMIA Beta Blockers “Inferior to Other Drugs,” Will Not Be Recommended as 1st–Line Treatments in New Hypertension GL
October 29, 2013
-
ORGANIZATION Generic Makers to Jointly Outsource GMP Inspections on Drug Substance Suppliers; Pilot to Begin by March
October 28, 2013
-
BUSINESS Teva’s Global Medical Director Says Biosimilars Can Cut Medical Costs
October 25, 2013
-
REGULATORY Regulatory Reform Council to Convene Public Discussion on Expansion of “Mixed Healthcare” on November 28
October 25, 2013
-
REGULATORY Diovan Panel Should Question 4 Key Figures to Dig into Scandal Further: Expert Member
October 24, 2013
-
REGULATORY MOF Demands Hefty Price Cuts for Long-Listed Products, Skeptical about Premium
October 23, 2013
-
BUSINESS Swiss Novartis Sees 22% Plunge in January-September Diovan Sales
October 23, 2013
-
ORGANIZATION No Clear Violation of Fair Competition Code in Diovan Case: Maker FTC Exec
October 22, 2013
-
BUSINESS Wholesalers’ Sluggish Price Settlement Rate Could Mar Reliability of Market Price Survey
October 22, 2013
-
ORGANIZATION JPMA Will Announce Response to Violation of PAL by Mitsubishi Tanabe in Near Future: Director General Goto
October 21, 2013
-
REGULATORY Ex-Health Minister Nagatsuma Eyes Unsworn Diet Testimony by Ex-Novartis Employee on Diovan Scandal
October 18, 2013
-
REGULATORY CSIMC Pricing Subcommittee OKs Indicator to Gauge Reasonableness of Premium’s Perpetuation
October 17, 2013
-
BUSINESS Gilead to Fully Enter Japan, File for Approval for Hepatitis C Treatment Sofosbuvir in 2014: President
October 16, 2013
ページ
A Japanese drug pricing panel on November 11 discussed ways to respond to the US most-favored-nation (MFN) policy, with healthcare…
On paper, things should be looking up for Japan’s pharmaceutical wholesalers. Industry expectations are mounting that the average gap between NHI and market prices will narrow further in FY2026 from the previous year’s record low of 4.8%.A shrinking gap should…
Japan is set to add 16 new drugs to its NHI reimbursement price list on November 13, including a subcutaneous…
Tariffs have been a defining feature of US trade policy under President Donald Trump’s second administration. Since Trump unveiled his “reciprocal” tariff policy in April 2025, the landscape has shifted repeatedly.In February 2026, the US Supreme Court invalidated tariffs imposed…
Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…